Research program Live corpus

Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.

PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 40,351 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

Explore Platform → See latest papers

40,351 Papers indexed

1,440 Papers AI scored

40,351 Ranked papers

100.0% Coverage

Featured discovery ● Live

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

AI Score 79.80 Active signal

Grade A

Final score 88.16

Narrative velocity Not calculated

Confidence Building

CHIP-AML22 is a multinational pediatric de novo AML trial protocol integrating risk-adapted therapy, randomized gemtuzumab ozogamicin and consolidation-course comparisons, subgroup-specific quizartinib, and toxicity-reduction measures.

Read full analysis →

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE

↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing

TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

Published Jun 20, 2026

Journal Trials

88.16 Ranking score

A grade PMID 42321916

View analysis →

Bicistronic CD19/CD22 CAR T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.

Published Sep 03, 2026

Journal JAMA oncology

87.88 Ranking score

A grade PMID 42690647

View analysis →

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

Published Jul 01, 2026

Journal The Lancet. Oncology

87.73 Ranking score

A grade PMID 42372741

View analysis →

Umbilical cord blood natural killer cells improve anti-GD2 antibody efficacy in neuroblastoma: from mouse to human.

Published May 30, 2026

Journal Oncoimmunology

87.38 Ranking score

A grade PMID 42216567

View analysis →

Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trial.

Published Mar 31, 2026

Journal BMJ (Clinical research ed.)

87.15 Ranking score

A grade PMID 41916649

View analysis →

Therapy and biomarker dependent progression-free survival in infant sonic hedgehog medulloblastoma: a multi-national retrospective cohort study.

Published May 18, 2026

Journal EClinicalMedicine

86.97 Ranking score

A grade PMID 42382416

View analysis →

Integrated biomarker and treatment correlates of prognosis in infant non-WNT/non-SHH medulloblastoma: a multinational retrospective cohort study.

Published May 18, 2026

Journal The Lancet. Child & adolescent health

85.99 Ranking score

A grade PMID 42150584

View analysis →

Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia.

Published Sep 17, 2026

Journal The New England journal of medicine

85.54 Ranking score

B grade PMID 42748428

View analysis →

Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS -mutant neuroblastoma.

Published Feb 20, 2026

Journal bioRxiv : the preprint server for biology

85.22 Ranking score

A grade PMID 41756844

View analysis →

A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.

Published Sep 21, 2026

Journal Blood cancer discovery

85.08 Ranking score

A grade PMID 42765973

View analysis →

T-cell receptor-engineered T-cell therapy using a glypican-3-specific TCR derived from a hepatoblastoma vaccine responder for HLA-A2-positive glypican-3-expressing cancers.

Published Jun 26, 2026

Journal Cancer letters

85.07 Ranking score

A grade PMID 42362103

View analysis →

Gilteritinib and chemotherapy in children with relapsed/refractory FLT3-ITD AML: results from the phase 1/2 SKIPPER trial.

Published Jul 14, 2026

Journal Blood advances

84.86 Ranking score

A grade PMID 42101908

View analysis →

LATEST PEDIATRIC CANCER PAPERS

Database feed

Last ingest 2026-11-12 10:15 AM

1 Interventions to reduce paediatric cancer treatment abandonment in low-income and middle-income countries: a systematic review and meta-analysis. The Lancet. Global health — Nov 12, 2026 2 Paediatric cancer treatment abandonment: multifaceted solutions required. The Lancet. Global health — Nov 12, 2026 3 Conjunctival inflammatory myofibroblastic tumour in infancy: diagnostic challenges and sequential histopathological evolution. BMJ case reports — Nov 12, 2026 4 Genome-wide association study meta-analysis identifies susceptibility loci informing Ewing sarcoma etiology and potential mechanisms of risk. Cell genomics — Nov 12, 2026 5 Getting on the "same page": Couples' experiences communicating about hereditary cancer risk and family building decisions. Journal of psychosocial oncology — Nov 12, 2026 6 SPROUT Guidelines for Molecular Profiling for Children with Solid Tumors: A Consensus Recommendation from the American Association for Cancer Research. Clinical cancer research : an official journal of the American Association for Cancer Research — Nov 12, 2026 7 Association of medical play therapy with psychological resilience during chemotherapy in children with malignant lymphoma: a propensity score-weighted retrospective cohort study. Psychology, health & medicine — Nov 12, 2026 8 Expression patterns of hypoxia signaling pathway genes and their association with clinical biochemical parameters in acute myeloid leukemia patients of Assam: A case control study. Molecular biology reports — Nov 12, 2026

WHAT THE AI SEES TODAY

Live pediatric oncology intelligence

● Live

↗

Therapeutic signal strength is updating across newly scored pediatric oncology literature.

✦

Mechanism clusters are forming around tumor biology, immune response, targeted therapy, treatment resistance, and drug repurposing.

⌁

Daily literature intake feeds the ranking engine and refreshes study-design, human-relevance, and therapeutic-relevance scores.

●

40,351 pediatric cancer records are currently visible under this search.

PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

40351 results

The UNSCEAR 2020/2021 report's estimates of thyroid exposure from the Fukushima nuclear accident contain over 100 problems.

PMID 42029674 Published: 2026-04-24 Ingested: 2026-08-02 12:06 AM Annals of the ICRP

AI -

Standard 37.4

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 37.4/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 22.0; sample size: 20.0; recency: 100.0; abstract quality: 65.0.

Child with mucoepidermoid carcinoma of the trachea.

PMID 41932710 Published: 2026-04-03 Ingested: 2026-08-02 12:06 AM BMJ case reports

AI -

Standard 37.4

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 37.4/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 22.0; sample size: 20.0; recency: 100.0; abstract quality: 65.0.

Pseudomyogenic Hemangioendothelioma With Novel NEDD9::FOSB Fusion Gene.

PMID 41887229 Published: 2026-03-26 Ingested: 2026-08-02 12:06 AM Pediatric dermatology

AI -

Standard 37.4

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 37.4/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 22.0; sample size: 20.0; recency: 100.0; abstract quality: 65.0.

DoBSeqWF: a framework for sensitive detection of individual genetic variation in pooled sequencing data.

PMID 41704565 Published: 2026-02-16 Ingested: 2026-08-02 12:06 AM NAR genomics and bioinformatics

AI -

Standard 37.4

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 37.4/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 22.0; sample size: 20.0; recency: 100.0; abstract quality: 65.0.

Progression from Peripheral to Central Precocious Puberty in a Child with Leydig Cell Tumor.

PMID 41486225 Published: 2026-01-05 Ingested: 2026-08-02 12:06 AM Indian journal of pediatrics

AI -

Standard 37.4

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 37.4/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 22.0; sample size: 20.0; recency: 100.0; abstract quality: 65.0.

Rethinking the definition of "combined retinal hamartoma": A call for taxonomical clarity.

PMID 41432690 Published: 2025-12-23 Ingested: 2026-08-02 12:05 AM European journal of ophthalmology

AI -

Standard 37.4

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 37.4/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 22.0; sample size: 20.0; recency: 100.0; abstract quality: 65.0.

Secular trend of cervical cancer mortality in Brazil and regions.

PMID 40136166 Published: 2023-12-30 Ingested: 2026-08-02 12:04 AM Ciencia & saude coletiva

AI -

Standard 37.4

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 37.4/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 22.0; sample size: 20.0; recency: 80.0; abstract quality: 85.0.

Life and Times of Yellapragada SubbaRow.

PMID 39163070 Published: 2024-08-01 Ingested: 2026-08-02 12:02 AM The Journal of the Association of Physicians of India

AI -

Standard 37.4

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 37.4/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 22.0; sample size: 20.0; recency: 80.0; abstract quality: 85.0.

Fraction of cancers attributable to and prevented by reproductive factors and exogenous hormones use in Italy.

PMID 39094535 Published: 2024-07-05 Ingested: 2026-08-02 12:02 AM European journal of obstetrics, gynecology, and reproductive biology

AI -

Standard 37.4

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 37.4/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 22.0; sample size: 20.0; recency: 80.0; abstract quality: 85.0.

Barriers and Facilitators to Youth Decision-Making Involvement in Families Referred for Stem Cell Transplant.

PMID 39066518 Published: 2024-07-27 Ingested: 2026-08-02 12:02 AM Journal of family nursing

AI -

Standard 37.4

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 37.4/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 22.0; sample size: 40.0; recency: 80.0; abstract quality: 65.0.

Autopsy case of linear nevus sebaceous syndrome with KRAS (G12D) mutation.

PMID 38994806 Published: 2024-07-12 Ingested: 2026-08-02 12:02 AM Pathology international

AI -

Standard 37.4

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 37.4/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 22.0; sample size: 20.0; recency: 80.0; abstract quality: 85.0.

Analysis of the global burden of cervical cancer in young women aged 15-44 years old.

PMID 38756096 Published: 2024-08-01 Ingested: 2026-08-02 12:02 AM European journal of public health

AI -

Standard 37.4

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 37.4/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 22.0; sample size: 20.0; recency: 80.0; abstract quality: 85.0.

Page 3292 of 3363

Open the Research
Intelligence Map

Finding therapies hidden in 40,351 pediatric cancer papers.

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

Ranked Discovery Journal Articles

Database feed

All ranked pediatric cancer papers

AI-assisted research information

Open the Research Intelligence Map